Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Human herpesvirus 6 and CAR T-cell toxicity

Karl S. Peggs

Blood (2024) 144 (5): 465–466.

https://doi.org/10.1182/blood.2024024973

Published: 2024

Journal Articles

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Blood (2023) 141 (20): 2470–2482.

https://doi.org/10.1182/blood.2022018598

Published: 2023

Includes: Supplemental data

Journal Articles

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 7452–7453.

https://doi.org/10.1182/blood-2022-167053

Published: 2022

Journal Articles

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation

Blood (2021) 138 (Supplement 1): 1788.

https://doi.org/10.1182/blood-2021-146515

Published: 2021

Journal Articles

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Blood (2021) 138 (Supplement 1): 3823.

https://doi.org/10.1182/blood-2021-146316

Published: 2021

Journal Articles

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Mohamed Amine Bekadja, Ariane Boumendil, Sr., PhD, Didier Blaise, MD, Patrice Chevalier, MD PhD, Karl S Peggs, MD PhD, Gilles Salles, MD PhD, Sebastian Giebel, Sr., Jürgen Finke, Sr., MD PhD, William Arcese, MD PhD, Noel Milpied, Hervé Finel, Sr., MD PhD, Norbert Claude Gorin, Sr., MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-133900

Published: 2020

Journal Articles

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

Lorna Neill, Strachan C Mackenzie, MBBS, BSc, MRCP, Maria A V Marzolini, William Townsend, MRCP,MDFRCPath, Kirit M. Ardeshna, Kate Cwynarski, Surjo De, Vanya Gant, Lhara Mure, Sara McElduff, Chantelle Hughes, Karl S Peggs, MD PhD, Claire Roddie, PhD MD, Maeve A O'Reilly, MBBCHBAO

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-138865

Published: 2020

Journal Articles

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137768

Published: 2020

Journal Articles

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Blood (2019) 134 (Supplement_1): 1995.

https://doi.org/10.1182/blood-2019-124404

Published: 2019

Journal Articles

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

Claire Burney, MBBS, Stephen Robinson, MBBS, PhD BSc, Ariane Boumendil, PhD, Hervé Finel, Irma Khvedelidze, Hannah Hunter, MB,FRCPath,MRCP, Xavier Poire, Bruno Lioure, MD, Karl S Peggs, Robin Foà, MD, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Tom Van Meerten, MD PhD, Juan Jose Bargay, Christoph Schmid, MD, Vergote Vibeke, Arnold Ganser, MD, Luca Castagna, MD, Ghulam J. Mufti, Silvia Montoto, MD

Blood (2019) 134 (Supplement_1): 701.

https://doi.org/10.1182/blood-2019-123442

Published: 2019

Journal Articles

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Blood (2019) 134 (Supplement_1): 226.

https://doi.org/10.1182/blood-2019-131086

Published: 2019

Journal Articles

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Blood (2019) 134 (Supplement_1): 776.

https://doi.org/10.1182/blood-2019-129640

Published: 2019

Journal Articles

Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells

Maria A V Marzolini, Ayse Akarca, Karen Teng, Teresa Marafioti, MD, Satyen H Gohil, Amit C Nathwani, MD PhD, Evan Newell, PhD, Sergio A Quezada, Karl S Peggs

Blood (2018) 132 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2018-99-116798

Published: 2018

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

Paul Michael Maciocia, BSc,MBBS,MRCP, Patrycja Wawrzyniecka, MSc, Brian Philip, PhD, Ida Ricciardelli, PhD, Ayse U. Akarca, BSc, Shimobi Onuoha, PhD, David Cole, PhD, Andrew Sewell, PhD, Karl S Peggs, MD, David C. Linch, MD MRCP, MB BCh, BA, Teresa Marafioti, MD, Martin A Pule, MD PhD

Blood (2016) 128 (22): 811.

https://doi.org/10.1182/blood.V128.22.811.811

Published: 2016

Journal Articles

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells

Laurie Menger, Agnes Gouble, Maria A. V. Marzolini, Annette Pachnio, Katharina Bergerhoff, Jake Y. Henry, Julianne Smith, Martin Pule, Paul Moss, Stanley R. Riddell, Sergio A. Quezada, Karl S. Peggs

Blood (2015) 126 (26): 2781–2789.

https://doi.org/10.1182/blood-2015-08-664755

Published: 2015

Includes: Supplemental data

Journal Articles

CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status

Rob S. Sellar, Frederick Arce Vargas, Jake Y. Henry, Stephanie Verfuerth, Sarah Charrot, Brendan Beaton, Ronjon Chakraverty, Sergio A. Quezada, Stephen Mackinnon, Kirsty J. Thomson, Karl S. Peggs

Blood (2015) 125 (4): 731–739.

https://doi.org/10.1182/blood-2014-07-589150

Published: 2015

Includes: Supplemental data

Journal Articles

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

Karl S Peggs, Eleni Tholouli, Ronjon Chakraverty, PhD, Emmanouil Nikolousis, PhD, Adrian Bloor, PhD FRCPath, Stephen Devereux, MD PhD FRCPath, Kim H. Orchard, PhD, Charles Crawley, Anne Parker, Stephen P Robinson, PhD, Frederick Chen, MDPhD, Gordon Cook, MD, Richard E Clark, MBBS MD, Kirsty Thomson, Matthew Cobb, Katy Newton, PhD, Simon Thomas, PhD, Paul Moss, PhD

Blood (2014) 124 (21): 1109.

https://doi.org/10.1182/blood.V124.21.1109.1109

Published: 2014

Journal Articles

The Impact of Donor HLA Type on Characteristics of CMV-Specific T Cell Products: Experience from Two UK Randomized Trials

Amanda Skulte, BSc, MClinTRes, Arindam Mitra, BSc, Simon Thomas, PhD, Matthew Cobb, Alka Stansfield, Karl S Peggs, Katy Newton, PhD

Blood (2014) 124 (21): 1124.

https://doi.org/10.1182/blood.V124.21.1124.1124

Published: 2014

Journal Articles

Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma

Yasmin Reyal, Irfan Kayani, Ronjon Chakraverty, Adrian Bloor, PhD FRCPath, Christopher P Fox, Kirsty Thomson, Adele K. Fielding, Ben Taylor, Mark Bishton, Emma Morris, Nigel Russell, Stephen Mackinnon, Karl S Peggs

Blood (2014) 124 (21): 1225.

https://doi.org/10.1182/blood.V124.21.1225.1225

Published: 2014

NARROW

Human herpesvirus 6 and CAR T-cell toxicity

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry

Steroid Use, Advanced Stage Disease and ≥3 Lines of Prior Chemotherapy Are Associated with a Higher Risk of Infection Following CD19 CAR T-Cell Therapy for B-NHL: Real World Data from a Large UK Center

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

T-Cell Reconstitution after Unrelated Donor HSCT Using Immunotherapy with CD25/71 Allodepleted Donor T Cells: Results of the Randomised Icat Study

Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

Automated Manufacture of Matched Donor-Derived Allogeneic CD19 CAR T-Cells for Relapsed/Refractory B-ALL Following Allogeneic Stem Cell Transplantation: Toxicity, Efficacy and the Important Role of Lymphodepletion

Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Targeting T-Cell Receptor β-Constant Domain for Immunotherapy of T-Cell Malignancies

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells

CMV promotes recipient T-cell immunity following reduced-intensity T-cell–depleted HSCT, significantly modulating chimerism status

CMV~IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT

The Impact of Donor HLA Type on Characteristics of CMV-Specific T Cell Products: Experience from Two UK Randomized Trials

Pre-Transplantation FDG-PET Predicts Early but Not Late Survival Outcomes Following Allogeneic Transplantation in Chemo-Sensitive Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only